OSE Immunotherapeutics SA (OSE.PA) — Stock Score Summary

OSE Immunotherapeutics SA (OSE.PA) has a MoatMap StockRank of 9/100 based on Quality (31/100), Value (36/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL. OSE Immunotherapeutics is an early-stage biotechnology company with highly volatile cash flows and no established commercial product moat. It does not fit our CDMO pricing power theme as it is a drug developer rather than a scaled manufacturing partner, failing our quality compounder criteria.

OSE Immunotherapeutics SA is a clinical-stage French biotechnology company focused on developing innovative immunotherapies for cancer and autoimmune diseases. The company's competitive edge lies in its proprietary platforms, such as Memopi for neoepitope vaccines and its selective checkpoint inhibitors, which have attracted major pharmaceutical partnerships. It operates as a high-potential niche player in the global oncology and immunology R&D landscape.

Key Financial Metrics

Price$4.04
Market Cap$119M
P/E (Forward)-3.36
Price/Book2.44
Return on Equity-66.8%
Return on Invested Capital41.5%
Debt/Equity72.30
Gross Margin100.0%
Operating Margin-2272.2%
Revenue Growth-0.8%
Free Cash Flow$-23M

OSE Immunotherapeutics SA operates in the Biotechnology industry, part of the Healthcare sector (France).

Frequently Asked Questions

What is OSE Immunotherapeutics SA’s (OSE.PA) StockRank?
MoatMap’s StockRank for OSE Immunotherapeutics SA (OSE.PA) is 9/100, with a Strong Sell signal. It is a composite of Quality (31), Value (36), and Momentum (23) factor ranks across MoatMap’s 19,000+ stock universe.
Does OSE Immunotherapeutics SA have an economic moat?
OSE Immunotherapeutics SA (OSE.PA) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is OSE Immunotherapeutics SA a buy, hold, or sell?
MoatMap’s current signal for OSE Immunotherapeutics SA (OSE.PA) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is OSE Immunotherapeutics SA in?
OSE Immunotherapeutics SA (OSE.PA) operates in the Healthcare sector, specifically the Biotechnology industry (France).
Browse all ranked stocksOSE.PA deep dive reportAI ChampionsHow we score stocksSense-check another stock